The trial was completed in mid-January. Since then, the data has been unblinded and the topline report is being/has been prepared. It may have been already passed along to the FDA. The agency could grant leronlimab Emergency Use Authorization any day now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.